Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...